Journal
PHYTOTHERAPY RESEARCH
Volume 36, Issue 8, Pages 3265-3275Publisher
WILEY
DOI: 10.1002/ptr.7499
Keywords
chronic kidney diseases; FoxO1; muscle atrophy; resveratrol; SIRT1
Categories
Funding
- National Natural Science Foundation of China [82170750]
- Natural Science Foundation of Jiangsu Province
- Natural Science Foundation of China
Ask authors/readers for more resources
Chronic kidney disease (CKD) is often accompanied by muscle atrophy, and the application of resveratrol can improve renal function, reduce renal fibrosis, and alleviate muscle atrophy. SIRT1 plays a crucial role in linking renal disease and muscle atrophy, possibly through regulating FoxO1. Therefore, resveratrol and other SIRT1 agonists have great therapeutic potential for treating CKD and its related muscle atrophy.
Chronic kidney disease (CKD) is often associated with muscle atrophy. However, the underlying molecular mechanisms are still not well understood. Here, we treated 5/6-nephrectomized (5/6Nx) rats with resveratrol and found that this treatment greatly improves renal function as evidenced by reduced proteinuria and cystatin C. Moreover, resveratrol ameliorates renal fibrosis by reducing transforming growth factor beta (TGF-beta) and connective tissue growth factor (CTGF). Meanwhile, muscle atrophy in these 5/6Nx rats was largely attenuated by resveratrol. Immunoprecipitation revealed that SIRT1 physically interacts with FoxO1 in muscle, and this interaction was weakened in 5/6Nx rats. As a consequence, acetylated FoxO1 was increased in muscle of 5/6Nx rats. The application of resveratrol markedly reverses this trend. These data point out that SIRT1 is a key factor for linking renal disease and muscle atrophy. Indeed, both renal dysfunction and muscle atrophy were further aggravated by 5/6Nx in Sirt1(+/-) mice. Taken together, our data indicate that SIRT1 plays a pivotal role in muscle atrophy in CKD, and FoxO1 might be a substrate of SIRT1 in this process. Furthermore, resveratrol, together with other agonists of SIRT1, may hold great therapeutic potentials for treating CKD and its related muscle atrophy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available